{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972630",
  "id": "02972630",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250725",
  "time": "0922",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m4779dg2ckw5.pdf",
  "summary": "- **Clinical Hold Response Submitted**: Neurizon has submitted a formal response to the FDA to resolve the clinical hold on NUZ-001 for ALS treatment.  \n- **Key Data Included**: New bridging PK data from animal studies (rats and dogs) shows >10-fold safety margins for NUZ-001 and its metabolite.  \n- **FDA Review Timeline**: Feedback expected within 30 days (by late August 2025).  \n- **Next Milestone**: Target participation in HEALEY ALS Platform Trial by Q4 2025, pending FDA clearance.  \n\n*No capital markets or trading-specific actions (e.g., raising, halt) identified.*",
  "usage": {
    "prompt_tokens": 1365,
    "completion_tokens": 133,
    "total_tokens": 1498,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T23:32:20.777186"
}